ZFIN ID: ZDB-FISH-160104-16
Fish name: pd27Tg; zf169Tg
Genotype: pd27Tg; zf169Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by pd27Tg; zf169Tg
No data available
GENE EXPRESSION
Gene expression in pd27Tg; zf169Tg
RNA expression No data available
Protein expression No data available
PHENOTYPE
Phenotype in pd27Tg; zf169Tg
Phenotype Conditions Figures
dorsal aorta hematopoietic stem cell decreased amount, abnormal standard conditions Fig. 3 from Oo et al., 2017
hematopoietic multipotent progenitor cell amount, normal chemical treatment by environment: MMP9 inhibitor I Fig. 2 with image from Theodore et al., 2017
hematopoietic multipotent progenitor cell amount, normal chemical treatment by environment: N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide Fig. 2 with image from Theodore et al., 2017
hematopoietic multipotent progenitor cell amount, normal chemical treatment by environment: prinomastat hydrochloride Fig. 2 with image from Theodore et al., 2017
hematopoietic multipotent progenitor cell decreased amount, abnormal chemical treatment by environment: 4-chloro-L-phenylalanine Fig. 2 from Kwan et al., 2016
hematopoietic multipotent progenitor cell increased amount, abnormal chemical treatment by environment: cobalt dichloride Fig. 7 from Kwan et al., 2016
hematopoietic multipotent progenitor cell increased amount, abnormal chemical treatment by environment: cortisol Fig. 5Fig. 6 from Kwan et al., 2016
hematopoietic multipotent progenitor cell increased amount, abnormal chemical treatment by environment: dexamethasone Fig. 5 from Kwan et al., 2016
hematopoietic multipotent progenitor cell increased amount, abnormal chemical treatment by environment: 2-chloro-6-(1-piperazinyl)pyrazine Fig. 6 from Kwan et al., 2016
hematopoietic multipotent progenitor cell increased amount, abnormal chemical treatment by environment: serotonin Fig. 1Fig. 2Fig. 6 from Kwan et al., 2016
hematopoietic multipotent progenitor cell increased amount, abnormal chemical treatment by environment: fluoxetine Fig. 1 from Kwan et al., 2016
hematopoietic stem cell decreased amount, abnormal chemical treatment by environment: 17beta-estradiol Fig. 7 with image from Carroll et al., 2014
hematopoietic stem cell increased amount, abnormal chemical treatment by environment: estrogen receptor antagonist Fig. 7 with image from Carroll et al., 2014
hematopoietic stem cell cell population proliferation increased process quality, abnormal chemical treatment: cannabinoid receptor agonist Fig. 5 with image from Esain et al., 2015
ventral wall of dorsal aorta EGFP expression decreased amount, abnormal chemical treatment by environment: 17beta-estradiol Fig. 7 with image from Carroll et al., 2014
ventral wall of dorsal aorta EGFP expression increased amount, abnormal chemical treatment by environment: estrogen receptor antagonist Fig. 7 with image from Carroll et al., 2014
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell DsRed2 expression increased amount, abnormal chemical treatment by environment: serotonin Fig. 1 from Kwan et al., 2016
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell DsRed2 expression increased amount, abnormal chemical treatment by environment: fluoxetine Fig. 1 from Kwan et al., 2016
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell EGFP expression increased amount, abnormal chemical treatment by environment: fluoxetine Fig. 1 from Kwan et al., 2016
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell EGFP expression increased amount, abnormal chemical treatment by environment: serotonin Fig. 1 from Kwan et al., 2016
ventral wall of dorsal aorta hematopoietic stem cell decreased amount, abnormal chemical treatment: SC560 Fig. 4 with image from Esain et al., 2015
ventral wall of dorsal aorta hematopoietic stem cell decreased amount, abnormal chemical treatment: NS-398 Fig. 4 with imageFig. 5 with image from Esain et al., 2015
ventral wall of dorsal aorta hematopoietic stem cell decreased amount, abnormal chemical treatment: cannabinoid receptor agonist Fig. 2 with image from Esain et al., 2015
ventral wall of dorsal aorta hematopoietic stem cell decreased amount, abnormal chemical treatment: EC 2.7.11.* (protein-serine/threonine kinase) inhibitor Fig. 5 with image from Esain et al., 2015
ventral wall of dorsal aorta hematopoietic stem cell increased amount, abnormal chemical treatment: anandamide Fig. 1 with image from Esain et al., 2015
ventral wall of dorsal aorta hematopoietic stem cell increased amount, abnormal chemical treatment: 2-arachidonoylglycerol Fig. 1 with image from Esain et al., 2015
ventral wall of dorsal aorta hematopoietic stem cell increased amount, abnormal chemical treatment: cannabinoid receptor agonist Fig. 1 with imageFig. 2 with imageFig. 4 with imageFig. 5 with image from Esain et al., 2015

CITATIONS  (5)